



Case Studies of Successful Collaborations between Academia and Industry

Date: September 20th, 2011
Time: 9:00 am to 12:00 pm
Location: Lecture Hall: Samarkand

The session will give examples of beneficial partnership models of Academia with the Pharmaceutical Industry and highlight the outcome of their joint research efforts. We will hear how this new collaborative trend drives innovation in Pharmaceutical Research and question its sustainability.

Agenda:

- 9:00 – 9:05 Introduction
- 9:05 – 9:30 **Carole Fages** (Head of the E2C business development office, Sanofi):
“Access Platform: a New Way of Partnering”
- 9:30 – 9:55 **Bahne Stechmann** (Scientific Manager EU-OPENSREEN, FMP Berlin):
“EU-OPENSREEN –
A European Infrastructure of Open Screening Platforms for Chemical Biology”
- 9:55 – 10:20 **Ruth Wellenreuther** (Alliance Manager and Project Coordinator, DKFZ Heidelberg):
“DKFZ & Bayer HealthCare:
A Strategic Partnership in Translational Cancer Research and Drug Discovery”
- 10:20 – 10:45 **Oliver Koch** (BioChemInformatics Postdoctoral-Fellow, Intervet Innovation GmbH):
“CM-0801 New Drugs for Neglected Diseases”
- 10:45 – 11:10 **Philip Gribbon** (CSO/COO, European ScreeningPort GmbH):
“NEU² – A Competence Consortium for Drug Discovery Funded by the German
BioPharma Initiative”
- 11:10 – 11:35 **Tom Livelli** (Vice President, Life Sciences Products and Services, Promega Corporation):
“Promega’s Strategic Collaborations with Academia to Drive Innovative Research Tools
and Assays”
- 11:35 – 12:00 **Emilio Diez** (VP and Director Molecular Discovery Research, GSK):
“New Approaches to Improve Innovation through PPP”

Organizers: Phil Gribbon, European ScreeningPort (Chair)
Mira Grättinger, European ScreeningPort (Organizer)
Hubert Haag, Sanofi (Co-Organizer)

Session Sponsors:

Sanofi: www.sanofi.com

Enamine: Enamine Ltd (est. 1991) is a privately owned chemical company, expert in synthesis of Building Blocks and derived small molecular weight compound libraries, providing in-house made small molecule compound libraries, custom synthesis, hit-to-lead optimization. <http://www.enamine.net>

Bionamics: Bionamics is an asset management company, bridging the gap between excellent research projects and the industry’s need for pre-/clinical development programs. Bionamics typically identifies assets in the pre-clinical space, manages the development of those assets into drug candidates and supports the commercialization into the pharma and biotech industry. Bionamics offers a unique project based investment opportunity on a single asset or portfolio basis. <http://www.bionamics.de>